J Pediatr Genet 2020; 09(03): 164-170
DOI: 10.1055/s-0040-1701446
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Screening for the Most Common Mutations of CFTR Gene among Egyptian Children with Difficult-to-Treat Asthma

Mohammad Al-Haggar
1   Genetics Unit, Pediatrics Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
,
2   Pulmonology Unit, Pediatrics Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
,
1   Genetics Unit, Pediatrics Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
,
Tarek Barakat
1   Genetics Unit, Pediatrics Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
,
Samar El-Morsi
3   Pediatrics Department, Faculty of Medicine, Mansoura University Children's Hospital, Mansoura, Egypt
› Author Affiliations
Further Information

Publication History

15 September 2019

30 December 2019

Publication Date:
03 February 2020 (online)

Abstract

Cystic fibrosis (CF) is panethnic autosomal recessive disease that affects the exocrine glands of pancreas, lungs, and intestine. It is often misdiagnosed in developing countries as difficult-to-treat asthma. We enrolled 150 Egyptian families with one or more probands who were complaining of difficult-to-treat asthma, and 112 cases were studied extensively through history taking including pedigree construction and clinical examination. In addition, spirometry and computed tomography of the chest were done in selected cases. All cases were subjected to quantitative sweat chloride test and molecular screening for the three most common mutations of cystic fibrosis transconductance regulator (CFTR) gene (ΔF508, G542X, W1282X) using amplification refractory mutation system (ARMS) technique. Probands of difficult-to-treat asthma comprised 66 males and 46 females; their age range was 1 to 14 years. Sixty-one probands (54.5%) were carriers of one or more of the studied mutations (36 cases and 25 carriers). Six carriers of single mutations had mild respiratory symptoms and negative sweat test. The most common allele was ΔF508, 60 alleles in 56 individuals (4 were homozygous ΔF508/ΔF508) followed by W1282X in 25 individuals and G542X in 12 individuals. Allele W1282X had an increased risk of recurrent chest infection and bronchiectasis. Moreover, cases with two mutations had more severe symptoms compared with those with a single mutation. CFTR mutations and CF-related syndromes are not rare as thought in Egypt, especially among the high-risk difficult-to-treat asthma. The readily available ARMS technique is recommended for ΔF508 and/or W1282X screening on priority basis among these children.

 
  • References

  • 1 Awasthi S, Gupta S, Maurya N, Tripathi P, Dixit P, Sharma N. Environmental risk factors for persistent asthma in Lucknow. Indian J Pediatr 2012; 79 (10) 1311-1317
  • 2 Robinson D, Humbert M, Buhl R. , et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy 2017; 47 (02) 161-175
  • 3 Iordanidou M, Loukides S, Paraskakis E. Asthma phenotypes in children and stratified pharmacological treatment regimens. Expert Rev Clin Pharmacol 2017; 10 (03) 293-303
  • 4 Bel EH, Sousa A, Fleming L. , et al; Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66 (10) 910-917
  • 5 Farrell PM, White TB, Ren CL. , et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J Pediatr 2017; 181S: S4-S15 , 15.e1
  • 6 Cheng SH, Gregory RJ, Marshall J. , et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990; 63 (04) 827-834
  • 7 Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004; 23 (01) 146-158
  • 8 El-Falaki MM, Shahin WA, El-Basha NR, Ali AA, Mehaney DA, El-Attar MM. Profile of cystic fibrosis in a single referral center in Egypt. J Adv Res 2014; 5 (05) 563-568
  • 9 De Boeck K, Wilschanski M, Castellani C. , et al; Diagnostic Working Group. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61 (07) 627-635
  • 10 Global Initiative for Asthma. Global strategy for the diagnosis and prevention. 2016. Available at: www.ginasthma.com . Accessed on January 27, 2020
  • 11 Bombieri C, Claustres M, De Boeck K. , et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros 2011; 10 (02) (Suppl. 02) S86-S102
  • 12 Newton CR, Summers C, Heptinstall LE. , et al. Genetic analysis in cystic fibrosis using the amplification refractory mutation system (ARMS): the J3.11 MspI polymorphism. J Med Genet 1991; 28 (04) 248-251
  • 13 Tizzano EF, Buchwald M. Cystic fibrosis: beyond the gene to therapy. J Pediatr 1992; 120 (03) 337-349
  • 14 Rosenstein BJ, Cutting GR. ; Cystic Fibrosis Foundation Consensus Panel. The diagnosis of cystic fibrosis: a consensus statement. J Pediatr 1998; 132 (04) 589-595
  • 15 Ferrie RM, Schwarz MJ, Robertson NH. , et al. Development, multiplexing, and application of ARMS tests for common mutations in the CFTR gene. Am J Hum Genet 1992; 51 (02) 251-262
  • 16 Palomaki GE, FitzSimmons SC, Haddow JE. Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population. Genet Med 2004; 6 (05) 405-414
  • 17 CFTR2@Johns Hopkins—homepage [Internet]. Available at: http://cftr2.org/ . Updated August 2016. Accessed October 21, 2016
  • 18 Goubau C, Wilschanski M, Skalická V. , et al. Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis. Thorax 2009; 64 (08) 683-691
  • 19 Voter KZ, Ren CL. Diagnosis of cystic fibrosis. Clin Rev Allergy Immunol 2008; 35 (03) 100-106
  • 20 Abdel-Salam E, Samuel S, Awad M, El-Marsafy A, Abdel-Meguid IE, Azmy J. Cystic fibrosis in Egyptian children: neonatal screening and high risk groups. JAC 1993; 4 (04) 313-317
  • 21 Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168 (08) 918-951
  • 22 Al-Mahroos F. Cystic fibrosis in Bahrain incidence, phenotype, and outcome. J Trop Pediatr 1998; 44 (01) 35-39
  • 23 Shawky RM, Abdel Khalek KA, Abdel Fattah SM. , et al. Biochemical and molecular study of cystic fibrosis among high risk group patients with chronic lung disease. Egypt J Med Genet 2003; 4 (01) 97-112
  • 24 El-Falaki MM, Wilson MM, Ezzat GM, Mokhtar DA, El Baz MS, Hamed DH. A disintegrin and metalloproteinase 33 (ADAM33) gene polymorphism association with asthma in Egyptian children. Egypt J Med Hum Genet 2013; 14: 55-62
  • 25 Naguib ML, Schrijver I, Gardner P. , et al. Cystic fibrosis detection in high-risk Egyptian children and CFTR mutation analysis. J Cyst Fibros 2007; 6 (02) 111-116
  • 26 Dahl R, Nielsen LP, Kips J. , et al; SPIRA Study Group. Intranasal and inhaled fluticasone propionate for pollen-induced rhinitis and asthma. Allergy 2005; 60 (07) 875-881
  • 27 Schroeder SA, Gaughan DM, Swift M. Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis. Nat Med 1995; 1 (07) 703-705
  • 28 Munthe-Kaas MC, Lødrup Carlsen KC, Carlsen KH. , et al. CFTR gene mutations and asthma in the Norwegian Environment and Childhood Asthma study. Respir Med 2006; 100 (12) 2121-2128
  • 29 Douros K, Loukou I, Nicolaidou P, Tzonou A, Doudounakis S. Bone mass density and associated factors in cystic fibrosis patients of young age. J Paediatr Child Health 2008; 44 (12) 681-685
  • 30 Yoshida R, Ruge B. Diagnosis of cystic fibrosis in a patient of Egyptian background. BMJ Case Rep 2016; 2016: bcr2016217072